BiotechTube

Glucagon RTU

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperinsulinemic Hypoglycemia

Conditions

Hyperinsulinemic Hypoglycemia

Trial Timeline

May 10, 2019 → Feb 26, 2020

NCT ID
NCT03770637

About Glucagon RTU

Glucagon RTU is a phase 2 stage product being developed by Xeris Pharmaceuticals for Hyperinsulinemic Hypoglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03770637. Target conditions include Hyperinsulinemic Hypoglycemia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03770637Phase 2Completed

Competing Products

2 competing products in Hyperinsulinemic Hypoglycemia

See all competitors
ProductCompanyStageHype Score
PasireotideNovartisPhase 1
33
Dasiglucagon + PlaceboZealand PharmaPhase 2
49

Other Products from Xeris Pharmaceuticals

G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin])Phase 3
72
G-Pen + Novo GlucagonPhase 3
72
G-Pen + Lilly GlucagonPhase 3
72
GlucagonPhase 3
72
PRAM9 + Regular Insulin + Pramlintide + Regular InsulinPhase 2
47